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OBJECTIVES We hypothesized that elevated blood urea nitrogen (BUN) would be associated with adverse
outcomes independent of serum creatinine (sCr)-based estimates of kidney function in
patients with acute coronary syndromes (ACS).
BACKGROUND Although lower glomerular filtration rates (GFR) have prognostic significance among
patients with ACS, estimates of GFR based on sCr may perform less accurately among
patients with milder kidney dysfunction. In this population in particular, BUN, which can
reflect increased proximal tubular reabsorption in addition to decreased GFR, may have
independent prognostic value.
METHODS Data were drawn from 9,420 patients with unstable coronary syndromes from Orbofiban in
Patients With Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction
(OPUS-TIMI)-16, a trial that excluded patients with sCr1.6 mg/dl or estimated creatinine
clearance 40 ml/min.
RESULTS Patients with elevated BUN were older, had a higher prevalence of comorbidities, and
had higher heart rates, lower systolic blood pressures, and an abnormal Killip class more
often on admission. In univariate analyses, as well as in stratified and multivariable
analyses including sCr-based estimates of GFR as a covariate, a stepwise increase in
mortality occurred with increasing BUN (multivariable hazard ratio with BUN 20 to 25
mg/dl 1.9, 95% confidence interval 1.3 to 2.6; with BUN 25 mg/dl 3.2 [95% confidence
interval 2.2 to 4.7]) compared with BUN 20 mg/dl. A higher BUN was also associated
with increased mortality among strata of troponin-I, B-type natriuretic peptide, and
C-reactive protein concentrations.
CONCLUSIONS Among patients with unstable coronary syndromes and predominantly normal or mildly
reduced GFR, an elevated BUN is associated with increased mortality, independent of
sCr-based estimates of GFR and other biomarkers. (J Am Coll Cardiol 2005;45:1781–6)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.068© 2005 by the American College of Cardiology Foundation
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whe relationship between chronic kidney disease (CKD)
nd adverse cardiovascular outcomes is well established in
atients with acute coronary syndromes (ACS) (1–3).
ost prior studies have utilized serum creatinine (sCr),
stimated creatinine clearance (eCrCl), or sCr-based
stimates of glomerular filtration rate (eGFR) (4) to
ssess kidney function. However, estimates of kidney
unction based primarily upon sCr are imperfect and may
ot adequately assess acute changes in actual glomerular
ltration rate (GFR) or other aspects of kidney function,
articularly when the GFR is only mildly reduced (5,6).
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nd the ‡Department of Medicine, University of California, San Francisco, San
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Manuscript received December 20, 2004; revised manuscript received February 8,
005, accepted February 14, 2005.The blood urea nitrogen (BUN) concentration has
een considered a less specific marker of kidney function
han sCr, eCrCl, or eGFR. However, in addition to
eflecting GFR, BUN may rise independent of changes in
FR or sCr owing to enhanced proximal tubular reab-
orption under the activation of the sympathetic nervous
nd renin-angiotensin-aldosterone systems (7). Although
UN has been associated with adverse outcomes and has
een previously incorporated into myocardial infarction
isk prediction models (8,9), BUN has not been investi-
ated in ACS patients without myocardial infarction or
n conjunction with other measures of kidney function.
hus, whether BUN provides marginal predictive power
fter accounting for an sCr-based estimate of kidney
unction is unclear. In this study, we aimed to determine
hether there was an independent increase in risk ob-erved with higher BUN across strata of sCr, eCrCl, and
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BUN in ACS June 7, 2005:1781–6GFR and hypothesized that an elevated BUN would be
ssociated with adverse outcomes independent of other
linical and laboratory characteristics, including biomar-
er levels.
able 1. Baseline Characteristics
BUN <20 mg/dl
(n  7,796)
emographics
Age (yrs) 59 (51, 68)
Weight (kg) 80 (70, 90)
Male gender 72.6%
Current smoker 39.2%
History of congestive heart failure 3.6%
History of hypertension 40.5%
History of diabetes mellitus 19.3%
Hypercholesterolemia 28.4%
omorbidities
Prior myocardial infarction 26.7%
History of CKD 3.6%
History of vascular disease 6.3%
edications on admission
Aspirin 38.0%
Beta-blocker 27.2%
Calcium channel blocker 23.6%
Diuretic 11.1%
ACE inhibitor 18.4%
Cholesterol-lowering agents 20.2%
linical data
Hours from index to randomization 40 (25, 56)
Systolic blood pressure (mm Hg) 128 (113, 140)
Heart rate (beats/min) 70 (62, 80)
Killip class II–IV 6.6%
ST-segment deviation 70.5%
STEMI 32.8%
UA/non–STEMI 67.2%
Elevated cardiac markers (local) 70.6%
erum creatinine 0.8 (0.7, 0.9)
reatinine clearance 106.7 (83.7, 133.3)
stimated GFR (MDRD) 95.7 (82.3, 112.5)
K-MB ( upper limit of normal) 3.3 (1.0, 10.4)
hite blood cell count 7.9 (6.5, 9.7)
emoglobin 13.7 (12.8, 14.7)
RP (mg/l, n  3,143) 10 (4, 33)
NP (pg/ml, n  2,445) 74.8 (42.0, 128.2)
alues in parentheses indicate 25th and 75th percentiles.
Abbreviations and Acronyms
ACS  acute coronary syndromes
BNP  B-type natriuretic peptide
BUN  blood urea nitrogen
CKD  chronic kidney disease
CRP  C-reactive protein
eCrCl  estimated creatinine clearance
eGFR  estimated glomerular filtration rate
GFR  glomerular filtration rate
OPUS-TIMI-16  Orbofiban in Patients With Unstable
Coronary Syndromes-Thrombolysis
In Myocardial Infarction-16 trial
sCr  serum creatinineACE  angiotensin-converting enzyme; BNP  B-type natriuretic peptide; BUN  blo
-reactive protein; GFR  glomerular filtration rate; STEMI  ST-elevation myocardialETHODS
linical and laboratory data were drawn from 9,420 patients
ith ACS and available BUN data enrolled in the Orbofi-
an in Patients With Unstable Coronary Syndromes-
hrombolysis In Myocardial Infarction (OPUS-TIMI)-16
rial of the oral glycoprotein IIb/IIIa inhibitor orbofiban.
atients were eligible for enrollment if they presented
ithin 72 h of the onset of ischemic symptoms with
igh-risk features (10); patients with admission sCr 1.6
g/dl or eCrCl 40 ml/min were excluded owing to
oncerns regarding renal clearance of orbofiban. Patients
ith significant systemic bleeding were also excluded. Patients
ere randomly assigned to one of the following three treat-
ent arms: 50 mg orbofiban twice daily, 50 mg orbofiban
wice daily for one month followed by 30 mg orbofiban twice
aily, or placebo. Subject follow-up was obtained at a mini-
um of six months.
BUN 20–25 mg/dl
(n  1,029)
BUN >25 mg/dl
(n  595) p for Trend
67 (59, 74) 70 (63, 76) 0.001
78 (68, 88) 75 (68, 87) 0.001
72.3% 66.9% 0.01
23.7% 21.5% 0.001
11.3% 13.3% 0.001
52.7% 56.8% 0.001
27.5% 34.8% 0.001
29.2% 25.7% 0.38
32.1% 32.5% 0.001
3.7% 3.5% 0.96
11.1% 9.9% 0.001
46.7% 45.2% 0.001
30.7% 31.8% 0.001
30.3% 28.7% 0.001
23.0% 32.2% 0.001
29.2% 35.0% 0.001
21.9% 20.2% 0.54
42 (26, 59) 43 (26, 59) 0.03
130 (115, 145) 130 (110, 140) 0.20
72 (64, 80) 72 (64, 83) 0.001
15.2% 24.5% 0.001
74.9% 77.1% 0.001
30.6% 31.0% 0.15
69.4% 69.0%
68.9% 71.1% 0.72
1.0 (0.9, 1.2) 1.2 (1.0, 1.4) 0.001
77.7 (60.3, 96.7) 61.6 (48.7, 78.8) 0.001
74.5 (62.4, 89.1) 60.5 (48.9, 74.1) 0.001
2.3 (0.9, 9.9) 3.5 (1.0, 10.1) 0.46
8.2 (6.7, 10.2) 9.0 (7.1, 11.6) 0.001
13.6 (12.6, 14.5) 13.1 (12.0, 14.3) 0.001
10 (3, 34) 18 (6, 68) 0.001
101.2 (57.9, 188.2) 129.6 (72.3, 233.1) 0.001od urea nitrogen; CK  creatinine kinase; CKD  chronic kidney disease; CRP 
infarction; UA  unstable angina.
t
l
G
v
L
p
O
w
t
i
n
t
m
S
t
s
c
s
a
c
f
c
m
a
l
h
t
b
n
b
m
8
R
T
a
w
w
h
a
O
1
a
B
t
m
(
r
b
i
m
S
m
n
(
a
s
F
l
1783JACC Vol. 45, No. 11, 2005 Kirtane et al.
June 7, 2005:1781–6 BUN in ACSLaboratory data, including BUN, were obtained at the
ime of enrollment and were assayed at a central core
aboratory. The eCrCl was calculated by the Cockcroft-
ault equation. The eGFR was calculated using the abbre-
iated Modification of Diet in Renal Disease formula (4).
evels of C-reactive protein (CRP) were measured in 3,143
atients as part of a nested case-control study within the
PUS-TIMI-16 trial; B-type natriuretic peptide (BNP)
as measured in 2,445 patients in the orbofiban 50/50
reatment group; troponin-I was measured in 2,514 patients
n the placebo group. The core laboratory upper limit of
ormal for BUN was 25 mg/dl. Patients were divided into
hree groups: those with BUN 20 mg/dl, BUN 20 to 25
g/dl, and BUN 25 mg/dl.
tatistical analysis. Continuous variables are reported as
he median (25%, 75% interquartile range). Linear regres-
ion and the chi-square test and test for trend were used to
ompare variables across ordered categories. Kaplan-Meier
urvival curves and six-month event rates were estimated,
nd the log-rank test and test of trend were used for
omparisons among groups. Stratified analyses were per-
ormed to assess for potential confounding by significant
igure 1. Kaplan-Meier survival estimates by blood urea nitrogen (BUN)
evel.Figure 2. Association of blood urea nitrogen with 30-day recuovariates. Cox proportional hazards regression was used in
ultivariable analyses with mortality at the outcome vari-
ble, including as candidate covariates other known corre-
ates of mortality and baseline characteristics associated with
igher BUN (p  0.05) in univariate analyses. The propor-
ional hazards assumption for the model was confirmed. As
iomarker data were not available for all patients, these were
ot included as covariates in the initial multivariable model,
ut were included in stratified analyses and in further
ultivariable models. Analyses were performed using Stata
.2 (Stata Corp., College Station, Texas).
ESULTS
he median BUN was 15.1 mg/dl (12.0, 18.4). There was
stepwise increase in the degree of baseline comorbidity as
ell as in adverse presenting characteristics among patients
ith increasing BUN (Table 1). The frequency of a reported
istory of CKD before the index admission was similar
mong groups. Consistent with the exclusion criteria of the
PUS-TIMI-16 trial, the median sCr was 0.8 mg/dl (0.7,
.0), with a median eCrCl of 100.0 ml/min (77.1, 127.7)
nd a median eGFR of 91.9 ml/min/1.73 m2 (76.8, 108.8).
UN and cardiovascular outcomes. Higher concentra-
ions of BUN were associated with a stepwise increase in
ortality at 30 days and throughout the follow-up period
Fig. 1). Patients with higher BUN were more likely to have
ecurrent myocardial infarction and congestive heart failure
y 30 days (Fig. 2), were less likely to undergo revascular-
zation, were more likely to experience a stroke, and also had
ore frequent adjudicated bleeding events.
tratified analyses. The association between BUN and
ortality remained significant in analyses stratified by age,
ormal or abnormal eGFR (Fig. 3A), sCr 1.2 or 1.2
Fig. 3B), and eCrCl (Fig. 3C). Blood urea nitrogen was
ssociated with stepwise increases in mortality in all three
tudy treatment groups (to placebo or one of two doses ofrrent myocardial infarction and congestive heart failure.
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BUN in ACS June 7, 2005:1781–6rbofiban) and irrespective of the type of ACS: ST-segment
levation myocardial infarction (STEMI) (1.8% vs. 7.2% vs.
5.5%, p  0.001), non-STEMI (2.9% vs. 7.9% vs. 17.7%,
 0.001), and unstable angina (2.3% vs. 5.3% vs. 13.8%,
 0.001). Stepwise increases in mortality with higher
UN were also observed when the data were stratified by
he presence of ST-segment deviation; cardiac marker
levation, including baseline troponin-I status; and baseline
emoglobin.
Blood urea nitrogen was associated with increased mor-
ality when stratified by Killip class (Fig. 4A) and BNP level
n  2,445) (Fig. 4B). Among the 3,143 patients with
vailable CRP data, BUN was associated with increased
ortality when stratified by CRP using a cutpoint of 15
g/l, a value previously shown to offer discriminatory
apacity in the dataset.
ultivariable analyses. A stepwise increase in mortality
as observed with increasing levels of BUN (HR 1.9 [1.3 to
.6] with BUN 20 to 25 mg/dl; HR 3.2 [2.2 to 4.7] with
UN 25 mg/dl) in a multivariable model adjusting for
aseline covariates (Table 2). This association was un-
hanged when either eCrCl or sCr was substituted in the
odel in place of eGFR and when the model was limited to
atients without adjudicated bleeding complications during
he follow-up period. The independent and graded associ-
tion between BUN and mortality persisted after further
djustment for troponin-I, CRP, or BNP in patients in
igure 3. (A) Relation of blood urea nitrogen (BUN) and mortality estima
elation of BUN and mortality estimates at six months stratified by serum
y estimated creatinine clearance (CrCl).hom these data were available.
m
(ISCUSSION
hereas prior studies have demonstrated an association
etween CKD and adverse outcomes in patients with ACS,
he majority of these studies have employed creatinine-
ased metrics (sCr, eCrCl, or eGFR) to estimate kidney
t six months stratified by estimated glomerular filtration rate (eGFR). (B)
nine. (C) Relation of BUN and mortality estimates at six months stratified
igure 4. (A) Relation of blood urea nitrogen (BUN) and mortality
stimates at six months stratified by Killip class. (B) Relation of BUN andtes aortality estimates at six months stratified by B-type natriuretic peptide
BNP).
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June 7, 2005:1781–6 BUN in ACSunction. The present study adds to these observations by
emonstrating that BUN is associated with increased mor-
ality in a heterogeneous group of ACS patients with
ormal to mildly reduced GFR, independent of baseline
linical characteristics, sCr-based estimates of kidney func-
ion, and other biomarkers. These findings particularly
ighlight the importance and complexity of assessing kidney
unction among patients with ACS.
Both BUN and sCr are imperfect measures of kidney
unction and are influenced by factors other than GFR (11).
n particular, the BUN concentration is determined by the
alance of urea generation and excretion by the kidneys, the
atter being dependent on the extent of urea reabsorption.
rea is reabsorbed with sodium and water in the proximal
ubule in a passive process, whereas in the more distal
ephron, urea reabsorption is closely linked to water reab-
orption under the influence of antidiuretic hormone (12),
hich in turn is affected by angiotensin-II (7). Thus, in
ddition to reflecting GFR, an elevated BUN can further
eflect a state of renal hypoperfusion from hypovolemia,
enovascular disease, or reduced cardiac output (13,14). In
hese states, BUN may rise independent of a change in GFR
r sCr due to enhanced urea reabsorption under the activa-
ion of the sympathetic nervous and renin-angiotensin-
ldosterone systems (7), known correlates of cardiovascular
able 2. Multivariable Model of Mortality by Six Months
Variable
Hazard
Ratio 95% CI
p
Value
UN 20 mg/dl Reference — —
UN 20–25 mg/dl 1.86 1.30–2.65 0.001
UN 25 mg/dl 3.22 2.23–4.67 0.001
ge (per yr) 1.05 1.03–1.06 0.001
bnormal Killip class 1.79 1.32–2.45 0.001
iuretic use before to admission 1.75 1.29–2.37 0.001
aseline hemoglobin (per g/dl) 0.86 0.79–0.94 0.001
dmission systolic blood pressure
(per mm Hg)
0.99 0.98–1.00 0.002
istory of peripheral vascular
disease
1.58 1.14–2.18 0.006
istory of diabetes mellitus 1.41 1.07–1.86 0.015
eight (per kg) 0.99 0.98–1.00 0.021
levated cardiac markers 1.42 1.05–1.91 0.021
rbofiban 50 mg/30 mg
study group
1.43 1.05–1.95 0.022
dmission heart rate (beat/min) 1.01 1.00–1.02 0.029
GFR (ml/min/1.73 m2) 1.00 1.00–1.01 0.071
ours from index event to
randomization
1.00 0.99–1.00 0.197
T-segment deviation 1.21 0.89–1.65 0.217
rbofiban 50 mg/50 mg
study group
1.22 0.88–1.68 0.226
CE inhibitor use before
admission
1.19 0.88–1.62 0.264
ale gender 1.11 0.82–1.50 0.491
istory of congestive heart failure 1.12 0.76–1.65 0.573
istory of hypertension 0.99 0.75–1.32 0.953
I  confidence interval; eGFR  estimated glomerular filtration rate; other
bbreviations as in Table 1.isk. This may be of particular relevance in patients withilder reductions in GFR, such as those patients included
n the present analysis.
The majority of studies in patients with ACS have
ocused on sCr, eCrCl, and eGFR as the metrics of kidney
unction associated with adverse outcomes. The current
tudy demonstrates that the prognostic value of elevated
UN is independent of elevated sCr, eCrCl, and eGFR,
nd parallels observations among patients with congestive
eart failure (14,15). Although sCr-based estimates of
idney function did not appear to provide additional prog-
ostic value in the multivariable analysis after accounting for
UN, only 7.7% of patients in this study had moderate-
evere impairment of eGFR owing to the exclusion criteria
f the OPUS-TIMI-16 trial. This may have limited the
ower to detect differences in outcomes when combining
UN and sCr-based estimates of kidney function together.
lternatively, BUN may add prognostic value to sCr-based
stimates of kidney function primarily among patients with
ilder degrees of impairment in GFR, who constitute the
ajority of patients with ACS.
Notably, the association between BUN and cardiovascu-
ar outcomes remained significant across strata of other
iomarkers associated with increased cardiovascular risk,
amely troponin-I, BNP, and CRP. In addition, the asso-
iation between BUN levels and mortality was evident at
alues of 20 to 25 mg/dl, suggesting that even minimal
levations in BUN may be a marker of adverse outcomes.
tudy limitations. This analysis is a nonrandomized ret-
ospective analysis, and as such it is possible that both
dentified and unidentified confounders may have influ-
nced the outcomes despite attempts to control for these
actors through stratified and multivariable analyses. For
xample, the more prevalent use of diuretics at baseline
mong patients with elevated BUN may have been a
urrogate of greater risk conveyed through occult congestive
eart failure, other edematous states, or more profound
ypertension. More specific information regarding types of
edications (e.g., loop diuretics vs. thiazide diuretics, use of
ngiotensin receptor blockers) was not available. Further-
ore, clinicians were not blinded to patient laboratory data,
nd, as such, there may have been unmeasured treatment
ifferences among BUN groups that could have influenced
utcomes. Our observation of an independent association
etween BUN concentration and mortality in patients with
CS may also be explained by factors that increase urea
eneration as well as urea reabsorption, including increased
issue catabolism or high dietary protein intake.
eprint requests and correspondence: Dr. C. Michael Gibson,
50 Longwood Avenue, First Floor, Boston, Massachusetts
2115. E-mail: mgibson@perfuse.org.
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